White Paper: Top 7 Covid-19 Impacts on Global Regulatory Practices in Biotech Industries
Published November 2021
Abstract:
The pandemic has shifted our thinking about access to healthcare products and has resulted in rapid adaptation and changes to how the pharmaceutical industry advances innovations. These changes have impacted drug development cycles and permitted the creation of novel therapies in record time. This white paper provides insight on regulatory adaptations as a result of the pandemic and what practises are here to stay.
Keywords: Covid-19, drug development, pharmaceutical industry, biotech industries, biomanufacturing, therapeutic projects, infectious disease research, manufacturing services, medicines regulation, pharmacy industry, FDA, Health Canada, EMA
Click here to view White paper: Top 7 Covid-19 Impacts on Global Regulatory Practices in Biotech Industries